Abstract 1751P
Background
This study described testing for mutations in the RET gene among pts with sporadic and hereditary MTC, a crucial factor in selecting targeted therapy linked with improved treatment [tx] outcomes for pts with MTC.
Methods
Real-world data were drawn from the Adelphi Thyroid Cancer Disease Specific ProgrammeTM – a point-in-time survey conducted July-December 2020 primarily with medical oncologists and endocrinologists in clinical practice. Physicians in France [FR], Germany [DE], Italy [IT], Spain [ES] and the UK completed patient record forms for the next 4 consulting adult MTC pts, providing demographics and testing patterns.
Results
153 physicians (70% medical oncologists, 20% endocrinologists) provided data on 275 pts. 207 (75%) pts were tested for any RET gene mutation, of these 79 (38%) were positive. 91 (44%) were tested for both germline and somatic mutation, 73 (35%) for germline mutation, 43 (21%) for somatic mutation at any time; mean (SD) time to get results was 20.2 (15.6) days. 140 (68%) were tested post MTC diagnosis, 85 (41%) were tested before tx initiation. When tested, 69 (33%) had a known disease state, of which 50 (72%) had locally advanced or metastatic disease. 207 pts received on average 0.9 and 1.0 tests in the 12 months prior to data abstraction for germline and somatic RET gene mutations respectively. Data were captured for 203 tests. Polymerase chain reaction (PCR) (35%) and next generation sequencing (NGS) (30%) were most common methods used. Use of PCR and NGS varied across countries (PCR: ES 43%, UK 22%, NGS: UK 61%, ES 7%). Across all tests, tissue (51%) and blood (44%) were most frequent samples. 132 (86%) physicians reported testing pts for any RET gene mutations; highest among endocrinologists 29 (97%). Greatest barrier to RET gene testing cited was delay in getting results (26%) across EU5; in DE, cost (25%) and UK guideline restrictions (27%) were most cited.
Conclusions
Most physicians request a RET gene test for their pts with MTC. With the advent of increasingly individualised regimens, there remains a need to broaden RET gene testing amongst pts at diagnosis, during localised disease status, and prior to tx initiation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Adelphi Group.
Funding
Adelphi Group.
Disclosure
R. Williams: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Adelphi Real World: Adelphi Real World. L.M. Hess: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company. T. Puri: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company. M. Jen: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company. M. Kostikas: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Adelphi Real World: Adelphi Real World. A. Rider: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Adelphi Real World: Adelphi Real World. U. Kiiskinen: Financial Interests, Personal, Full or part-time Employment, Full-time employee of Eli Lilly and Company: Eli Lilly and Company.